
The withdrawal came on the eve of a Senate committee vote, leaving the FDA without a nominee as vaccine and mifepristone debates continue.
Provisions under House and Senate versions of prescription drug benefits legislation and their impact on FDA final rules regarding generic drug approvals under the Waxman-Hatch Act.






